Display options
Cite
Kim ST, Jang HL, Lee J, et al. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Transl Oncol. 2015;8(4):288-94doi: 10.1016/j.tranon.2015.06.001.
Kim, S. T., Jang, H. L., Lee, J., Park, S. H., Park, Y. S., Lim, H. Y., Choi, M. G., Bae, J. M., Sohn, T. S., Noh, J. H., Kim, S., Kim, K. M., Kang, W. K., & Park, J. O. (2015). Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Translational oncology, 8(4), 288-94. https://doi.org/10.1016/j.tranon.2015.06.001
Kim, Seung Tae, et al. "Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer." Translational oncology vol. 8,4 (2015): 288-94. doi: https://doi.org/10.1016/j.tranon.2015.06.001
Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Kim KM, Kang WK, Park JO. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer. Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. PMID: 26310375; PMCID: PMC4562974.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001.

Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer.

Translational oncology

Seung Tae Kim, Hye-Lim Jang, Jeeyun Lee, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Min Gew Choi, Jae Moon Bae, Tae Sung Sohn, Jae Hyung Noh, Sung Kim, Kyoung-Mee Kim, Won Ki Kang, Joon Oh Park

Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  2. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Biomedical Research Institute, Seoul, Korea.
  3. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  4. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  5. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: [email protected].

PMID: 26310375 PMCID: PMC4562974 DOI: 10.1016/j.tranon.2015.06.001

Abstract

BACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis of cancer cells. Hypermethylation of the promoter represses expression of the IGFBP-3 gene. We undertook this study to assess the impact of IGFBP-3 methylation on survival of early stage gastric cancer patients.

METHODS: Of the 482 tissue samples from gastric cancer patients who underwent curative surgery, IGFBP-3 methylation was tested in 138 patients with stage IB/II gastric cancer. We also analyzed IGFBP-3 methylation in 26 gastric cancer cell lines. IGFBP-3 methylation was evaluated by methylation-specific polymerase chain reaction (MethyLight). Statistical analyses, all two-sided, were performed to investigate the prognostic effects of methylation status of the IGFBP-3 promoter on various clinical parameters.

RESULTS: Hypermethylation of IGFBP-3 was observed in 26 (19%) of the 138 stage IB/II gastric cancer patients. Clinicopathological factors such as age, Lauren classification, sex, tumor infiltration, lymph node metastasis, and histologic grade did not show a statistically significant association with the methylation status of the IGFBP-3 promoter. Patients with a hypermethylated IGFBP-3 promoter had similar 8-year disease-free survival compared with those without a hypermethylated IGFBP-3 promoter (73% vs 75%, P = .78). In subgroup analyses, females, but not males, seemed to have poorer prognosis for DFS and OS in the subset of patients with IGFBP-3 methylation as compared with those without IGFBP-3 methylation (8-year DFS: 55.6% vs 71.6%, P = .3694 and 8-year overall survival: 55.6% vs 68.4%, P = .491, respectively) even with no statistical significance.

CONCLUSIONS: The status of IGFBP-3 methylation as measured by methylation-specific polymerase chain reaction proposed the modest role for predicting survival in specific subgroups of patients with early-stage gastric cancer who undergo curative surgery. However, this needs further investigation.

Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

References

  1. Eur J Cancer. 2001 Nov;37(17):2257-63 - PubMed
  2. J Biol Chem. 1993 May 25;268(15):11348-55 - PubMed
  3. Growth Horm IGF Res. 2000 Apr;10 Suppl A:S22-3 - PubMed
  4. Ann Oncol. 2005;16 Suppl 1:i22-3 - PubMed
  5. Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1279-85 - PubMed
  6. Postgrad Med J. 2005 Jul;81(957):419-24 - PubMed
  7. Gastroenterology. 1993 Jun;104(6):1595-604 - PubMed
  8. J Endocrinol. 2000 May;165(2):253-60 - PubMed
  9. Br J Cancer. 2007 May 21;96(10):1587-94 - PubMed
  10. Cancer. 2006 Jul 15;107(2):299-308 - PubMed
  11. Cancer Res Treat. 2002 Apr;34(2):77-83 - PubMed
  12. J Biol Chem. 1993 Dec 15;268(35):26045-8 - PubMed
  13. Oncogene. 2001 May 28;20(24):3139-55 - PubMed
  14. J Natl Cancer Inst. 2001 Sep 5;93(17 ):1330-6 - PubMed
  15. Nat Genet. 1999 Feb;21(2):163-7 - PubMed
  16. Yonsei Med J. 2009 Jun 30;50(3):407-13 - PubMed
  17. Cancer Lett. 2002 Feb 25;176(2):149-58 - PubMed
  18. Endocr Relat Cancer. 2006 Jun;13(2):357-77 - PubMed
  19. Trends Genet. 2000 Apr;16(4):168-74 - PubMed
  20. Oncogene. 2004 Aug 26;23(39):6569-80 - PubMed
  21. Cancer Causes Control. 2004 Mar;15(2):211-8 - PubMed
  22. J Biol Chem. 1997 May 2;272(18):12181-8 - PubMed
  23. Mol Endocrinol. 1995 Mar;9(3):361-7 - PubMed
  24. Int J Cancer. 2006 Sep 15;119(6):1396-402 - PubMed
  25. N Engl J Med. 2003 Nov 20;349(21):2042-54 - PubMed
  26. J Biol Chem. 2000 Dec 15;275(50):39174-81 - PubMed
  27. Hum Pathol. 2001 Aug;32(8):856-62 - PubMed
  28. N Engl J Med. 2001 Sep 6;345(10):725-30 - PubMed
  29. J La State Med Soc. 1999 Apr;151(4):218-23 - PubMed
  30. Oncogene. 2007 Mar 15;26(12):1811-9 - PubMed

Publication Types